Triumeq is used for the treatment of HIV infection. Dose: For adults, it is available as a fixed-dose combination tablet containing ABC/3TC/DTG (600/300/50mg) administered once daily. The combination is also recommended as a first-line ART regimen for children weighing less than 30 kg, with weight-based dosing.

Contraindication: Abacavir Hypersensitivity: It is strictly contraindicated in patients who have a suspected or confirmed previous hypersensitivity reaction to Abacavir. Once hypersensitivity occurs, the patient must never be re-challenged with the drug. Concomitant use of Dolutegravir with oxcarbazepine is contraindicated. Precaution: Hypersensitivity Reaction (HSR): Abacavir can cause a potentially fatal hypersensitivity reaction. Weight Gain: Integrase inhibitors, including Dolutegravir, are associated with increased weight gain. Patients should be counseled on healthy eating and physical activity. Hepatitis B: Exacerbation of Hepatitis B has been reported in patients upon the discontinuation of Lamivudine. Pregnancy: Dolutegravir is safe for use during pregnancy. Previous concerns regarding an increased risk of neural tube defects following Dolutegravir exposure at conception or early pregnancy are significantly lower than initial studies suggested. Abacavir and Lamivudine have some risks Breastfeeding: Dolutegravir is considered safe during breastfeeding, though Abacavir and Lamivudine are not safe Renal/Hepatic Impairment: Renal Impairment: Dolutegravir and Abacavir do not require dose adjustments for impaired renal function. However, Lamivudine requires a dose adjustment if creatinine clearance (CrCl) is <50 ml/min. Because the components are in a fixed-dose tablet, the combination cannot be dose-adjusted and is generally not recommended for patients with a CrCl <50 ml/min. Hepatic Impairment: Abacavir must be avoided in severe hepatic impairment, and its dose requires reduction in moderate to severe impairment. Dolutegravir should be used with caution in severe liver impairment, while Lamivudine requires no specific dose adjustment but should be used cautiously in decompensated liver disease.

Triumeq contains Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG), a fixed-dose combination antiretroviral therapy. It combines an integrase strand transfer inhibitor (Dolutegravir) with two nucleoside reverse transcriptase inhibitors (Abacavir and Lamivudine).

Abacavir: The most significant adverse effect is a potentially fatal hypersensitivity reaction characterized by fever, fatigue, malaise, nausea, vomiting, diarrhea, abdominal pain, shortness of breath, and skin rash. Pancreatitis and lactic acidosis with hepatic steatosis are rare. Lamivudine: Headache, fatigue, nausea, diarrhea, skin rash, pancreatitis, peripheral neuropathy, and hepatotoxicity/hepatitis. Dolutegravir: The most common side effects are headache, nausea, and diarrhea, which usually resolve on their own. Increased weight gain is also noted.

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Because patients often purchase over-the-counter antacids or mineral supplements, it is critical to educate them about the interactions with Dolutegravir to avoid compromising their HIV treatment. Furthermore, rapid diagnosis and immediate discontinuation of the drug are vital if an Abacavir hypersensitivity reaction is suspected